Please: Login/Register

The Latest Edition of "Eyes on malaria" magazine will be out very soon!! | CALL FOR ARTICLES: AMMREN is inviting journalists / writers / scientists interested in reporting on malaria to send articles for publication in its international magazine “Eyes on Malaria” and for posting on its website. Please contact the AMMREN Secretariat for more details click here. Enjoy your stay!. Volunteers and interns urgently needed to work with an NGO working in the area of malaria and health. Apply through - / Journalists interested in reporting on and writing articles on health issues should please reply through this email:




    Mosquitoes around the home can be reduced significantly by minimizing the amount of standing water available for mosquito breeding. Residents are urged to reduce standing water around the home in a variety of ways.


    The best way is to avoid being bitten by mosquitoes.This can be accomplished using personal protecting  while outdoors when mosquitoes are present. Treated bed nets should be used sleeping. Mosquito repellent should be used when outdoor.


    Nearly half of the world’s population is at risk of getting malaria. Pregnant women are particularly at risk of malaria. Children under 5 years are at high risk of malaria.


  • First Edition

  • Second Edition

  • Third Edition

  • Fourth Edition

  • Fifth Edition

  • Sixth Edition

  • Seventh Edition

  • Eighth Edition

  • Ninth Edition

  • Special Edition

  • INESS Edition

  • Tenth Edition

  • INDEPTH Edition

  • Eleventh Edition

  • Twelfth Edition

  • Special Edition

  • Special Edition

  • Volume 1


In the August 2006 Malaria Vaccine Technology Roadmap, the global health community set goals to develop a malaria vaccine by 2015. RTS,S is on track to meet the target. If all goes well, the first results of vaccine trials being conducted in seven African countries will be released this year.

Indeed some progress has been made fighting this menace with existing tools like insecticide treated bed nets (ITNs), indoor residual spraying (IRS) and artemisinin-based combination therapies (ACT). But there is still a lot more to do to meet the target.

Malaria continues to claim as many as three thousand lives a day and a combination of factors account for this situation. These include the challenges of drug resistance due to drug misuse, use of mono-therapies, wrong diagnosis and the refusal of people to adhere to doctors’ advice.

Probably, the real answer to malaria lies in a vaccine to prevent rather than cure the disease. That is why we salute the organizations and individuals who have worked tirelessly towards developing a malaria vaccine.

The Malaria Clinical Trials Alliance (MCTA), of the INDEPTH Network, stands out as the only Africa-led project committed to building the capacity of African scientists to lead the search of a malaria vaccine. Over the years, the MCTA team has provided vital equipment and strengthened the capacity of the eleven trial site in seven African countries. This edition of Eyes on Malaria celebrates the achievements of the MCTA project as it comes to an end.

The partnership between leading African research institutions, their Northern partners, the PATH Malaria Vaccine Initiative (MVI) and GSK Biologicals, with grant monies from the Bill & Melinda Gates Foundation, has kept a good thing going towards an epoch-making conclusion.

Editorial Team
Charity Binka                        - Managing Editor
Carlton Cofie                         - Editor
Eunice Menka                       -Assistant Editor
Elizabeth Gyemfa Anim         – Editorial Assistant


Sixth Edition